Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2001 May;107(10):1219-20.
doi: 10.1172/JCI13073.

Osteolysis and cancer

D Goltzman  1
Affiliations
Comment

Osteolysis and cancer

D Goltzman. J Clin Invest. 2001 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of tumor-cell induced osteolysis. A tumor cell may release soluble mediators such as hormones (e.g., PTHrP), eicosanoids, cytokines (e.g., IL-6), or growth factors (e.g., TGF-α) that act on an osteoblastic stromal cell. The stromal cell produces RANKL, which binds to its cognate receptor, RANK, expressed on osteoclast (Oc) precursors. In the presence of M-CSF, which acts on its receptor, c-fms, RANKL can enhance the formation of active osteoclasts that carry out bone resorption. Tumor cells have also been occasionally reported to directly release sRANKL, a soluble form of RANKL. Additionally, proteases can be produced by tumor cells and facilitate their invasion of nonmineralized tissue.
See this image and copyright information in PMC

Comment on

References

    1. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80:1581–1587. - PubMed
    1. Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer. 2000;88:2903–2908. - PubMed
    1. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature. 1978;276:726–728. - PubMed
    1. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp. 2001;232:235–247; discussion 247–250. - PubMed
    1. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000;21:495–502. - PubMed